BKCa potassium channel agonists (Amgen)

N/A

Report date: 2025/03/14 20:00:48

NME

Base Information

Drug NameBKCa potassium channel agonists (Amgen)

Drug Alias NameMaxi K potassium channel agonists (Amgen)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionCalcium-activated potassium channel alpha/beta 1 agonists

TargetsCalcium-activated potassium channel alpha/beta 1

Therapy Area/IndicationsMigraine Disorders

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAmgen Inc

Active IndicationsN/A

Inactive IndicationsMigraine Disorders

ATC CodeN/A